Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition Nes Ziona, Israel, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported positive top-line results of an...

Enlivex Announces Allowance of New Chinese Patent Covering Allocetra Immunotherapy Nes-Ziona, Israel, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company, today announced that the China National Intellectual Property Administration...

Enlivex Announces Dosing of First Patient in Clinical Trial of Allocetra in COVID-19 Patients with Severe Illness Respiratory Failure Nes Ziona, Israel, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that the first patient has been dosed in an...

Enlivex Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference Nes Ziona, Israel, June 01, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that management will present a corporate...

Enlivex Announces Positive Final Safety and Efficacy Data From Clinical Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis – Final Analysis Comparing 10 AllocetraTM-Treated Patients with 37 Matched Controls Showed Significant Positive Responses in State of Organ Failure, ICU Hospitalization and Mortality in a Highly...